Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Expenditures: 2011-2024

Historic Capital Expenditures for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $8.2 million.

  • Adma Biologics' Capital Expenditures rose 1260.61% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 263.76%. This contributed to the annual value of $8.2 million for FY2024, which is 72.42% up from last year.
  • Latest data reveals that Adma Biologics reported Capital Expenditures of $8.2 million as of FY2024, which was up 72.42% from $4.8 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Capital Expenditures ranged from a high of $13.9 million in FY2022 and a low of $4.8 million during FY2023.
  • For the 3-year period, Adma Biologics' Capital Expenditures averaged around $9.0 million, with its median value being $8.2 million (2024).
  • Per our database at Business Quant, Adma Biologics' Capital Expenditures plummeted by 65.70% in 2023 and then spiked by 72.42% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Capital Expenditures stood at $12.7 million in 2020, then rose by 6.16% to $13.5 million in 2021, then grew by 2.96% to $13.9 million in 2022, then slumped by 65.70% to $4.8 million in 2023, then spiked by 72.42% to $8.2 million in 2024.